Tarsus Pharmaceuticals, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
TARS Company Description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
TARS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view TARS Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of TARS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TARS's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of TARS in WallStreetBets Daily Discussion
TARS News
Recent insights relating to TARS
CNBC Recommendations
Recent picks made for TARS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in TARS
Corporate Flights
Flights by private jets registered to TARS
Our Analysis